Edaravone
CAS 89-25-8
Edaravone (CAS 89-25-8) is a Phase 4 pharmaceutical compound with 1 bioactivity target and 155 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | AC50 | 27070.109024390244 nM | 41 | - |
| - | Potency | 25519.744 nM | 38 | - |
| - | IC50 | 21335.27176470588 nM | 16 | - |
| - | EC50 | 5127.5 nM | 4 | - |
| Polyunsaturated fatty acid lipoxygenase ALOX15 Enzyme |
IC50 | 4.47 | - | Mus musculus |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Death | 213 | 351.672 | 10011906 |
| Cerebral infarction | 67 | 210.898 | 10008118 |
| Disease progression | 57 | 84.851 | 10061818 |
| Amyotrophic lateral sclerosis | 16 | 76.564 | 10002026 |
| Haemorrhagic cerebral infarction | 15 | 75.728 | 10019005 |
| Hepatic function abnormal | 35 | 72.372 | 10019670 |
| Haemorrhagic infarction | 12 | 65.075 | 10019013 |
| Respiratory failure | 42 | 57.637 | 10038695 |
| Pneumonia aspiration | 28 | 53.431 | 10035669 |
| Gastrostomy | 11 | 51.424 | 10048978 |
| Paratonia | 6 | 48.9 | 10082325 |
| No adverse event | 25 | 44.557 | 10067482 |
| Cerebral haemorrhage | 23 | 42.572 | 10008111 |
| Drug ineffective | 96 | 40.564 | 10013709 |
| Cerebral hyperperfusion syndrome | 6 | 39.66 | 10064730 |
| Aphasia | 20 | 38.646 | 10002948 |
| Subarachnoid haemorrhage | 16 | 37.845 | 10042316 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| EDARAVONE | 1921877 | SU | MTHSPL |
| edaravone | 1921877 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Edaravone used for in pharmaceutical contexts?
Edaravone (CAS 89-25-8) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Edaravone?
Edaravone has 155 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Death, Cerebral infarction, Disease progression, Amyotrophic lateral sclerosis, Haemorrhagic cerebral infarction. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Edaravone also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Phenyl Methyl Pyrazolone with EU status "restricted".
What clinical phase is Edaravone in?
Edaravone is rendered with ChEMBL max phase 4 (approved).
What bioactivity targets are documented for Edaravone?
Edaravone has 5 bioactivity rows in this page query. Rendered target entries include Polyunsaturated fatty acid lipoxygenase ALOX15.